Tell Us Why You’re Attending!

 

#10: You can learn the latest trends in IP and business litigation.

 

#9:  CLE credit.

 

#8: It’s a great opportunity to network with in-house counsel & more.

 

#7: Cool dine-arounds at some of the hottest NY restaurants.

 

#6:  The best in biz will be sharing their advocacy skills.

 

#5: Learning how to manage all your information without losing your mind.

 

#4: Did we mention the networking receptions?

 

#3: Protecting your client’s business & IP interests is a must.

 

#2:  Because the Yankees aren’t the only sluggers in town!

 

And Reason #1: It’s the DRI in the Big Apple! Need we say more?

 

Register Now and Tell Us Why You’re Attending!

 

Bookmark and Share

 

With recent amendments to Federal Rule of Civil Procedure 26 and a proliferation of Motions to Strike/Exclude Expert Testimony under the Court’s responsibility as a gatekeeper of information that is to be considered by a jury, keeping apprised of recent rulings on these issues is key to effectively using experts in defending mass tort claims. This presentation will discuss the changes to Rule 26, including how courts have handled discovery disputes involving experts, and will address recent Daubert and Frye decisions that may assist in having an opponent’s experts testimony stricken before presentation to a jury as well as other considerations as you work on expert preparation for mass tort cases. 

To hear the entire presentation and three other timely and important topics relating to Mass Torts and Class Actions, please join us Wednesday afternoon at 3:30pm at the Mass Torts and Class Actions SLG presentation. You'll be glad you did. 
Bookmark and Share

 

In “RULE OF EVIDENCE 703 — Problem Child of Article VII (Sept. 19, 2011),” I wrote about how Federal Rule of Evidence 703 is generally ignored and misunderstood in current federal practice.  The Supreme Court, in deciding Daubert, shifted the focus to Rule 702, as the primary tool to deploy in admitting, as well as limiting and excluding, expert witness opinion testimony.  The Court’s decision, however, did not erase the need for an additional, independent rule to control the quality of inadmissible materials upon which expert witnesses rely.  Indeed, Rule 702 as amended in 2000, incorporated much of the learning of the Daubert decision, and then some, but it does not address the starting place of any scientific opinion:  the data, the analyses (usually statistical) of data, and the reasonableness of relying upon those data and analyses.  Instead, Rule 702 asks whether the proffered testimony is based upon:

1. sufficient facts or data,
2. the product of reliable principles and methods, and
3. a reliable application of principles and methods to the facts of the case

Noticeably absent from Rule 702, in its current form, is any directive to determine whether the proffered expert witness opinion is based upon facts or data of the sort upon which experts in the pertinent field would reasonably rely.  Furthermore,  Daubert did not address the fulsome importation and disclosure of untrustworthy hearsay opinions through Rule 703.  See Problem Child (discussing the courts’ failure to appreciate the structure of peer-reviewed articles, and the need to ignore the discussion and introduction sections of such articles as often containing speculative opinions and comments).  See also Luciana B. Sollaci & Mauricio G. Pereira, “The introduction, methods, results, and discussion (IMRAD) structure: a fifty-year survey,” 92 J. Med. Libr. Ass’n 364 (2004); Montori, et al., “Users’ guide to detecting misleading claims in clinical research reports,” 329 Br. Med. J. 1093, 1093 (2004) (advising readers on how to avoid being misled by published literature, and counseling readers to “Read only the Methods and Results sections; bypass the Discuss section.”)  (emphasis added).

Given this background, it is disappointing but not surprising that the new Reference Manual on Scientific Evidence severely slights Rule 703.  Using either a word search in the PDF version or the index at end of book tells the story:  There are five references to Rule 703 in the entire RMSE!  The statistics chapter has an appropriate but fleeting reference:

“Or the study might rest on data of the type not reasonably relied on by statisticians or substantive experts and hence run afoul of Federal Rule of Evidence 703. Often, however, the battle over statistical evidence concerns weight or sufficiency rather than admissibility.”

RMSE 3d at 214. At least this chapter acknowledges, however briefly, the potential problem that Rule 703 poses for expert witnesses.  The chapter on survey research similarly discusses how the data collected in a survey may “run afoul” of Rule 703.  RMSE 3d at 361, 363-364.

The chapter on epidemiology takes a different approach by interpreting Rule 703 as a rule of admissibility of evidence:

“An epidemiologic study that is sufficiently rigorous to justify a conclusion that it is scientifically valid should be admissible,184 as it tends to make an issue in dispute more or less likely.185"

Id. at 610.  This view is mistaken.  Sufficient rigor in an epidemiologic study is certainly needed for reliance by an expert witness, but such rigor does not make the study itself admissible; the rigor simply permits the expert witness to rely upon a study that is typically several layers of inadmissible hearsay.  See “Reference Manual on Scientific Evidence v3.0 – Disregarding Study Validity in Favor of the “Whole Gamish” (Oct. 14, 2011) (discussing the argument put forward by the epidemiology chapter for considering Rule 703 as an exception to the rule against hearsay).

While the treatment of Rule 703 in the epidemiology chapter is troubling, the introductory chapter on the admissibility of expert witness opinion testimony by the late Professor Margaret Berger really sets the tone and approach for the entire volume. See Berger, “The Admissibility of Expert Testimony,” RSME 3d 11 (2011).  Professor Berger never mentions Rule 703 at all!  Gone and forgotten. The omission is not, however, an oversight.  Rule 703, with its requirement of qualifying each study relied upon as having been “reasonably relied upon,” as measured by what experts in the appropriate discipline, is the refutation of Berger’s argument that somehow a pile of weak, flawed studies, taken together can yield a scientifically reliable conclusion. See “Whole Gamish,” (Oct. 14th, 2011).

Rule 703 is not merely an invitation to trial judges; it is a requirement to look at the discrete studies relied upon to determine whether the building blocks are sound.  Only then can the methods and procedures of science begin to analyze the entire evidentiary display to yield reliable scientific opinions and conclusions.


The author, Nathan A. Schachtman, is in private practice in New York City, and is a lecturer-in-law at the Columbia Law School.  He keeps a web log of musings on tort and evidence law at his website: schachtmanlaw.com

Bookmark and Share

 

The Topps Company (“Topps”) is suing fellow baseball trading card manufacturer Leaf Trading Cards (“Leaf”) for copyright and trademark infringement in a lawsuit recently filed in federal court (The Topps Company, Inc. v. Leaf Trading Cards, LLC, USDC SDNY, No. 11-civ-5585).  Topps claims that Leaf does not have the right to use pictures of old Topps cards featuring the company’s logos and players it has under exclusive contract.  The dispute arose over Leaf’s recent advertisement for its “2011 Leaf Best of Baseball” product.  The Best of Baseball pack, available to collectors, consists of one Leaf-created cut signature card and a PSA or BGS graded and authenticated card previous issued by various other manufacturers.  Some of the cards included in the packs are a 1952 Topps Mickey Mantle, a 1972 Carlton Fisk rookie, a 2001 Albert Pujols rookie, as well as cards autographed by teenage phenom Bryce Harper. One-pack boxes have been selling at retail for $235-275.

In addition to Topps’ claim that it owns the copyrights of the images on the cards and the logos, Topps further claims that it owns the rights to the player’s names and autographs.  In its complaint, Topps asserts that Leaf’s sell sheet is a “blatant attempt at capitalizing on Topps’ goodwill and intellectual property to advertise and promote Leaf’s product” (Complaint ¶48). On the packaging of its product Leaf included a disclaimer about the cards that are pictured at the bottom of the sell sheet.  Despite Leaf’s disclaimer, Topps asserts the use of its pictures will cause confusion in the marketplace stating: “[w]ithout exclusivity, the license’s value is highly diminished, both to Topps and the exclusive players.” 

In deciding this issue a judge must determine how far Topps’ rights extend with regard to products that were previously released and now are being repackaged for customers. 

http://www.sportscollectorsdaily.com/topps-sues-leaf-over-2011-best-of-baseball-sell-sheet/ 
Bookmark and Share

 

Litigation Funding Equals Big Money

Posted on October 6, 2011 02:18 by Terrence L. Graves

The Wall Street Journal (“WSJ”) reported in the October 3, 2011 edition of the paper about the start-up of three brand new companies that were started with the purpose of entering what is considered the “fledging alternative litigation funding market.”  You can view the article here.  

The WSJ identifies the three new players in this market as BlackRobe Capital Partners, LLC, Fulbrook Management LLC, and Bentham Capital LLC.  What is ultimately interesting about the article is not that there are three new sources of alternative litigation funding now available, but the fact that it points out a level of investment in high stakes commercial litigation by alternative litigation funding companies of which many lawyers in smaller law firms are simply unaware.  

Many of us think of a sleazy operation that takes advantage of personal injury plaintiffs by lending them money at usurious interest rates in order to “tide them over” until they are able to settle their personal injury law suits when the term alternative litigation funding is used.  This practice is widespread throughout the United States and is only regulated in a few jurisdictions.  These include:  Ohio, Rhode Island, Florida, Maine, and Nebraska.  These states only mandate that the lending entity be licensed and that proper disclosures be made of the applicable interest rates.

The lenders discussed in the WSJ article are looking for what are described as “huge, untapped market[s] for betting on high stakes commercial claims.”  It was reported that companies that would be involved in litigation will spend $15.5 billion in commercial litigation and an additional $2.6 billion on intellectual property litigation.  The practice apparently has what is described as “cautious backing” from several “big law” firms, including Latham & Watkins, LLP, Patton Boggs LLP, and Cadwalader, Wickersham & Taft LLP.  The bottom line is that many firms see this as a way to engage in litigation while making sure that legal fees are paid in a timely fashion.  

There is no question that allowing smaller companies to tap this source of funding would allow them to potentially go against much larger companies in litigation and, might be considered to be a way of leveling the playing field.  On the other hand, critics of this practice have indicated that allowing alternative litigation funding increases the likelihood of frivolous claims and would continue to mean an increase in litigation that would continue to deplete resources from what many already consider to be an over-whelmed legal system.

In some cases, the litigation that is generated is between the alternative litigation funder and the borrower.  This circumstance is discussed in a companion article found as an insert in the Wall Street Journal here.  The case that is the subject of this article resulted in a law suit in which the alternative litigation funder is seeking to recoup its “investment” of $3 million that was provided to fund litigation involving the plaintiff’s international arbitration claim against the nation of Romania.  

No matter which side of the debate you come down on with regards to alternative litigation funding, one thing is clear.  This is a subject that is gaining momentum in the legal community on several levels.  The DRI’s Public Policy Committee, chaired by John C. Trimble of Lewis Wagner, LLP in Indianapolis is looking at this issue and will be providing recommendations to the Executive Committee of DRI in the near future.  


Bookmark and Share

 

The Commercial Litigation Committee's April 2009 Symposium is open for registration. Running April 22-24, 2009, in Chicago, this seminar will include substantial presentations on the Financial and Credit Crisis, Business Torts and Class Actions, ADR, and Intellectual Property Litigation. We'll have a great faculty, ranging from the former Chief Economist of the Comptroller of the Currency, to in-house counsel, to leading litigators. Folks can get more information at http://www.dri.org/open/SeminarDetail.aspx?eventCode=20090036.

Contact me or other committee leaders to find out more, and join us in Chicago.

Joseph Fortner
Chair, DRI Commercial Litigation Committee
fortner@halloran-sage.com

Bookmark and Share

 
 

Submit Blog

If you wish to submit a blog posting for DRI Today, send an email to today@dri.org with "Blog Post" in the subject line. Please include article title and any tags you would like to use for the post.
 
DRI President's Blog
 
 

Search Blog


Recent Posts

Categories

Authors

Blogroll



Staff Login